Previous 10 | Next 10 |
Lipocine Inc. (LPCN) is expected to report $-0.57 for Q3 2023
Lipocine to Present Clinical Data on LPCN 1148 at The Liver Meeting® 2023 PR Newswire "Late Breaking" abstract scheduled for oral presentation on November 13 SALT LAKE CITY , Nov. 1, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceuti...
Lipocine Completes Successful Meeting with FDA on LPCN 1154 in Postpartum Depression PR Newswire Lipocine and FDA agreed on the acceptance criteria for the pivotal study which enables advancement of LPCN 1154 for postpartum depression (PPD) Company on track to initia...
Lipocine to Present at the H.C. Wainwright Annual NASH Investor Conference PR Newswire SALT LAKE CITY , Oct. 23, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today annou...
2023-10-10 07:35:13 ET More on Akero Akero Therapeutics: An Assessment Biggest stock movers today: Hyatt Hotels, PagerDuty and more Cantor starts Akero at buy, bullish on upcoming data for NASH drug Seeking Alpha’s Quant Rating on Akero Therapeutics ...
Lipocine to Present at the Cantor Fitzgerald Global Healthcare Conference PR Newswire SALT LAKE CITY , Sept. 19, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today annou...
2023-08-17 08:33:44 ET Tremor International ( TRMR ) -24% on Q2 earnings release . KULR Technology ( KULR ) -24% . on proposed stock offering ; Q2 earnings release . Hawaiian Electric Industries ( HE ) -20% on talks with financial restructurin...
2023-08-10 11:04:26 ET Lipocine press release ( NASDAQ: LPCN ): Q2 GAAP EPS of -$0.68 misses by $0.04 . As of June 30, 2023, Lipocine had $25.8 million of unrestricted cash, cash equivalents and marketable investment securities compared to $32.5 million at December ...
Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2023 PR Newswire SALT LAKE CITY , Aug. 10, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today ...
2023-07-27 13:46:53 ET More on Lipocine Lipocine stock dips after bridging study data of LPCN 1154 for postpartum depression Lipocine announces plans to focus on treating CNS disorders, shares rise ~5% Lipocine announces FDA accepted the marketing application for Tla...
News, Short Squeeze, Breakout and More Instantly...
Lipocine Announces Financial Results for the First Quarter Ended March 31, 2024 PR Newswire SALT LAKE CITY , May 9, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company, today announced financial results for the first quarter ended&...
Lipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at EASL Congress 2024 PR Newswire SALT LAKE CITY , May 8, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company, today announced that data from...
Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154 PR Newswire Pivotal study design aligned with FDA on streamlined pathway to NDA submission goal in 2024 Topline results anticipated late in 2Q 2024 SALT LAKE CITY ...